Site icon International Cytokine & Interferon Society

Daniel Cua is recognized as the 2023 ICIS-BioLegend William E. Paul Award winner for his profound & sustained impact on the field of cytokine biology

2023 ICIS BioLegend William E. Paul Recognizes Daniel Cua for his profound & sustained impact on the field of cytokine biology

From Left: Craig Monell, BioLegend; Daniel Cua; Hiroki Yoshida (ICIS Awards Committee Chair)
Christopher Hunter (ICIS President) presenting the 2023 ICIS-BioLegend William E. Paul Award to Dr. Cua

2023 ICIS-BioLegend William E. Paul Award for Excellence in Cytokine Research 

Daniel J. Cua, PhD, Vice President, Immunology, Distinguished Fellow, at the Janssen Research & Development, LLC, US

Daniel Cua has been selected as the recipient of the 2023 ICIS-BioLegend William E. Paul Award in recognition for his profound and sustained impact on the field of cytokine biology.

2023 ICIS-BioLegend William E. Paul Award for Excellence in Cytokine Research Presentation

Dr. Cua will give his ICIS-BioLegend Award Presentation at Cytokines 2023 in the Opening Session on Sunday, October 15th at the Divani Caravel Hotel in Athens on “Past, Present, and Future of IL-23 pathway biology.”

Dan does not have the typical career path of the majority of ICIS award recipients, but rather his seminal studies that defined the Th17 subset and the cytokines that control this pathway were performed while he was a research fellow at DNAX in Palo Alto shortly after getting his PhD in Microbiology and Immunology from 

Dan’s generosity with ideas and reagents and support of the field have been a major factor in allowing the field to advance. From his critically important seminal studies that defined the Th17 subset and the cytokines that control this pathway to his impactful work on Treg cells, his body of work has been foundational for the development of new strategies to treat multiple human disorders that are mediated by the IL-23/Th17 axis.

While the impact of Dan’s work on basic immunology would be sufficient to warrant his selection for this prestigious award – it is critical to acknowledge that this body of work was foundational for the development of new strategies to treat multiple human disorders that are mediated by the IL-23/Th17 axis.

  • Vice President, Immunology, Distinguished Fellow, at the Janssen Research & Development, LLC, US, where he oversees the IL-23 pathway scientific programs. Dan focuses his deep knowledge and expertise in cytokine biology to communicate Janssen’s strategic commitment in the IL-23 /Th17 pathway to global stakeholders.
  • A recognized leader in the field of IL-23 and Th17 immune pathway, which play critical roles in the pathogenesis of many autoimmune diseases. His work has significantly impacted the field of immunology and has led to the development of drugs that target IL-23 and Th17 cells.
  • His publications are widely cited (>57,000 times; h-index 70) and have appeared in prestigious journals such as Nature, Cell, Nature Medicine, Nature Immunology, JEM, JCI, and Immunity. He is recognized as a top 1% highly cited immunologists and one of the most influential scientists in biomedical research.
  • Dan holds 7 granted patents, which form the basis of immune therapy for the treatment of IL-23- and Th17-mediated inflammatory diseases. His patents were cross-licensed by Bio-Pharma for clinical testing and treatment of skin, joint, and gut diseases such as PSO, PSA, UC, CD, PPP, GCA, SS, LN.
  • Dan enjoys diving with sharks, windsurfing under the golden gate, and hiking to ends of the Earth.

 

Exit mobile version